Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae

Objectives: To analyse the strains collected during a 1-year survey of ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae, in order to investigate the molecular mechanisms potentially responsible for their resistant phenotype. Methods: Clinical KPC-producing K. pneumoniae isolates were collected from 31 patients in six different hospitals in Rome. For eight of the patients, an additional strain grown before the start of treatment was also available, bringing the total of isolates studied to 39. Antimicrobial susceptibility was determined by automated system, broth microdiluition and E-test as appropriate. In silico analysis of acquired resistance genes was achieved by whole-genome sequencing, while multilocus sequence typing and core genome multilocus sequence typing were employed for molecular typing. Mutations associated with ceftazidime-avibactam resistance were identified by Sanger sequencing of the bla(KPC) gene. Possible mutations in OmpK35 and OmpK36 outer membrane proteins were also investigated. Results: Molecular analyses highlighted the circulation of the ST512, 101 and 307 high-risk clones; 26 of the 31 patients carried a mutated KPC variant, five had a wild-type KPC-3. Among the KPC variants detected, 11 were different mutations within the bla(KPC-3) gene, four of which were novel mutational changes. Conclusions: Different mutations including single amino-acid substitutions, insertions or deletions within the bla(KPC) gene were found in 26/31 ceftazidime-avibactam-resistant KPC-producing K. pneumoniae strains belonging to high-risk clones circulating in Italy. Of note, in 14/31 cases the isolates displayed resistance to both ceftazidime-avibactam and carbapenems, raising concerns for the possible selection of a multidrug-resistant phenotype. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Automated summary

The study analyzed ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae strains collected from 31 patients in six hospitals in Rome, revealing mutations in KPC variants within the bla(KPC-3) gene and the presence of high-risk clones (ST512, 101, and 307). The findings highlight concerns over the potential selection of a multidrug-resistant phenotype in strains showing resistance to both ceftazidime-avibactam and carbapenems.